Edition:
United States

Ampio Pharmaceuticals Inc (AMPE.A)

AMPE.A on American Stock Exchange

2.96USD
16 Feb 2018
Change (% chg)

$-0.50 (-14.45%)
Prev Close
$3.46
Open
$3.50
Day's High
$3.50
Day's Low
$2.82
Volume
348,594
Avg. Vol
174,070
52-wk High
$4.93
52-wk Low
$0.38

Chart for

About

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for... (more)
No analyst recommendations are available for .

Overall

Beta: 0.03
Market Cap(Mil.): $195.47
Shares Outstanding(Mil.): 66.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Ampio Pharma Reports Positive Results For Ampion Phase 3 Trial In Severe Osteoarthritis-Of-Knee

* AMPIO PHARMACEUTICALS REPORTS POSITIVE RESULTS FOR BOTH PRIMARY AND SECONDARY ENDPOINTS OF PHASE 3 TRIAL OF AMPION IN SEVERE OSTEOARTHRITIS-OF-KNEE

Dec 14 2017

BRIEF-ACT Capital Management reports 5.5 pct passive stake in Ampio Pharma‍​‍​

* ACT Capital Management LLLP reports 5.5 percent passive stake in Ampio Pharmaceuticals Inc as on October 18, 2017‍​‍​ Source text : (http://bit.ly/2hhFhr9) Further company coverage:

Oct 27 2017

BRIEF-Ampio Pharmaceuticals enteres into securities purchase agreement for $6.75 mln shares

* Ampio Pharmaceuticals, Inc announces pricing of registered direct offering

Oct 16 2017

BRIEF-Ampio announces accepted publication of pooled Ampion™ clinical trial results

* Ampio announces accepted publication of pooled Ampion™ clinical trial results in patients with severe osteoarthritis of the knee

Oct 12 2017

BRIEF-Ampio discloses receipt of notice from NYSE American

* Ampio discloses receipt of notice from NYSE American and has until March 1, 2019, to gain compliance Source text for Eikon: Further company coverage:

Sep 07 2017

BRIEF-Ampio Pharmaceuticals appointed Thomas E. Chilcott, III, co's interim CFO, as CFO effective as of August 16, 2017.

* Ampio Pharmaceuticals- co announced that it appointed Thomas E. Chilcott, III, company s interim CFO, as CFO effective as of August 16, 2017. Source text: (http://bit.ly/2gnqo94) Further company coverage:

Aug 29 2017

Competitors

Earnings vs. Estimates